Certain information set forth in this website contains “forward-looking information”, including “future oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vi) renewal of the Company’s current customer, supplier and other material agreements; and (vii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.
These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this website are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
TRICCAR Holdings, Inc., dba TRICCAR, is a vertically integrated pioneer in bioceutical development. Hyporad™ is our proprietary Hypothesis-based Rapid Prototyping bioceutical development process. BIO and BioMedTracker’s collection and review of drugs in development found 4,000+ drugs from both publicly traded and private companies. The average success rate for successfully bringing a drug to market is roughly one-in-ten; just 9.6%.
In contrast, since redesigning our internal processes in Nov. 2016 to incorporate Hyporad, TRICCAR has maintained a development success rate exceeding 64%.
TRICCAR Holdings, Inc. is a privately-held Nevada C-corporation headquartered in Las Vegas, Nevada.
TRICCAR has one of the most diverse senior management teams in our industry, with 6 of our 10 (60%) key executives being minorities/women.
Our founder, Bill Townsend, was part of the founding/senior management teams at companies like Ketchum, Lycos, GeoCities (sold to Yahoo!), Deja.com (sold to Google and ebay), sixdegrees (the intellectual property behind LinkedIn), with exits over $9 billion. When creating TRICCAR, he pulled together great talent that has each been touched by health issues in their families. Bill serves as President & Chief Executive Officer.
Our CFO, Katrina Yao, is a CPA, Certified Internal Auditor, and Certified Information System Auditor with a superior track record, including as head of global finance of $2.8 billion retailer newegg.com.
Our SVP, Science, David Yang, spent 17 years at Procter and Gamble developing nutritional products. He holds 12 patents.
Our SVP, Products, Chuck Gagel, spent 30+ years at P&G, mostly in creating and clinical testing of products, with significant experience in sports nutrition.
Our SVP, Sales & Marketing, Brian Kalinowski, brings over 15 years of C-Level experience with roles at Lycos, LiveClips(acquired by DirecTV), and WWE (responsible for $100M in annual revenue).
TRICCAR's VP, DOJ/DEA Relations, William Simpson, Jr., spent 32 years and retired from the United States Drug Enforcement Administration as Chief of Operations Management Worldwide.
Dianna Ritchie, our VP, Human Resources, has over 20 of years in human resources management and talent development for manufacturing and consumer goods companies.
Last, but not least, our VP, Clinicals, Deborah Taylor, was formerly Executive Director at the University of Kentucky.
TRICCAR's Scientific Advisory Board includes world class physicians and researchers, including:
Dr. Timothy Charlton, a leading foot and ankle specialist at Cedars-Sinai Medical Center in Los Angeles. He is a graduate of Columbia University College of Physicians and Surgeons and a member of the American Board of Orthopaedic Surgeons and the American Academy of Orthopaedic Surgeons.
Dr. Thomas Tobin, MVB, MSc, PhD, MRCVS, AMAORC,is a research PhD specializing in Pharmacology at the University of Kentucky. He is the author of over 300 papers and inventor of the ELISA test. His congenital toxoplasmosis patent was licensed to Bayer Animal Science, which was turned into a $100M product.
Dr. Alden Townsend is a plant geneticist who spent much of his career at the United States National Arboretum. He has published more than 100 scientific and popular works. He earned his B.S. in Forest Science from Penn State University, an M.F. in genetics and ecology from Yale and a Ph.D. in forest genetics and plant breeding from Michigan State University.
Dr. Yossi Tam is Head of Obesity and Metabolism Laboratory, and Director Multidisciplinary Center for Cannabinoid Research at The Hebrew University of Jerusalem. He is widely considered one of the world’s foremost cannabinoids researchers.
Dr. Joy Kong is a UCLA-trained, triple board-certified physician (American Board of Psychiatry & Neurology, American Board of Addiction Medicine, and American Board Anti-Aging & Regenerative Medicine). She is the president of The Center for Regenerative Medicine in Los Angeles and a board member of American Association of Stem Cell Physicians.
Dr. Jonathan Kanevsky graduated with top honors from McGill University Faculty of Medicine and is an expert on Artificial Intelligence in health care. He was awarded The Charles E. FrosstMedical Prize and is the recipient of The Plastic Surgery Foundation Innovation Award.
Dr. Stefanie Tan is an internist specializing in diabetes. She is a faculty physician at the Internal Medicine Center of Summa Health System in Akron, Ohio.
Dr. Gregory Vassilev is a board-certified anesthesiologist and an interventional pain management specialist whose specializes in the management of complex pain, joint rejuvenation, and addiction medicine. He is a graduate of the David Geffen School of Medicine at UCLA.
Our powerhouse marketing team has past success launching and building brands including P90X, Sean T, Hip Hop Abs, Tony Horton's 10 Minute Trainer, Airborne, neurobrands, Shakeology, Bruce Tea, Marley Beverages, plus large brand experience with Pepsi, Dr. Pepper, 7-Up, Procter & Gamble, IBM, Citibank, BMW, and others. This team, along with those who work in each leader's group, represents some of the best bioceutical and marketing professionals in America.
TRICCAR owns and deploys patented and patent-pending marketing solutions and proprietary direct response marketing approaches. When used across health care, nutrition, fitness, and nutraceutical products, our platform has historically produced $139 in sales for every $7.60 spent, which far outstrips industry averages.
Our marketing platform has been used to successfully introduce and sell dozens of products over the past 12 years across multiple industries and countries. Examples of its effectiveness includes generating $75.2 million in the first year for a fitness and nutraceutical products provider and over $280 million for a multi-product online retailer’s marketplace.
Combined with our in-house television production, photography, design, and direct response teams, a superb manufacturing and logistics group, and a rock-solid finance group, TRICCAR is well positioned for future success.
Many of our team members have worked together in past companies and all are connected by the desire to provide effective, low-cost support to provide people around the world with hope for a better tomorrow.
TRICCAR is represented by a world-class team of partners, including:
7825 Fay Ave., Suite 200
La Jolla, CA 92037 USA
Attention: Mr. William Valladolid, Managing Partner
M. Richard Cutler, Esq.
2800 Post Oak Blvd.
Houston, TX 77056 USA
Want to learn more about TRICCAR and the amazing discoveries we've made?
Copyright © 2014 -2021 TRICCAR Holdings , Inc. - All Rights Reserved.
TRICCAR, the TRICCAR mark, TRICCAR Holdings, Townsend Rockefeller Institute for Cannabis Cultivation and Research are copyrights and/or trademarks of TRICCAR Holdings, Inc.
No part of this site may be reproduced without written permission.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Test results are available upon signing of a non-disclosure agreement and approval of TRICCAR management. User results and opinions of user experiences are the sole opinions of people who used these formula/ae and are not to be construed as claims made by TRICCAR or its affiliates.
Contact us at Hope @ TRICCAR . com
TRICCAR takes the spread of viruses seriously. We are ramping production of our AVL™ antiviral and IMX™ immunity support products to make them available to governments and health care oriented nonprofits and NGOs.